Resveratrol induces colon tumor cell apoptosis independently of p53 and preceded by epithelial differentiation, mitochondrial proliferation and membrane potential collapse

被引:143
作者
Mahyar-Roemer, M
Katsen, A
Mestres, P
Roemer, K
机构
[1] Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany
[2] Univ Saarland, Sch Med, Inst Anat, D-6650 Homburg, Germany
关键词
apoptosis; differentiation; mitochondria; resveratrol; p53;
D O I
10.1002/ijc.1516
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Resveratrol, a polyphenol present in wine and grapes, can inhibit tumor cell growth in vitro and tumorigenesis in vivo. Some of its effects have been linked to activation of the p53 tumor suppressor; however, p53 is frequently mutated in tumors, particularly in the common and often therapy-resistant colon cancers. Using the human wild-type p53-expressing HCT 116 colon carcinoma cell line and HCT 116 cells with both p53 alleles inactivated by homologous recombination, we show in the current study that resveratrol at concentrations comparable to those found in some foods can induce apoptosis independently of p53. The cell death is primarily mitochondria-mediated and not receptor-mediated. No cells survived in cultures continuously exposed to 100 muM resveratrol for 120 hr. When compared with 5-FU, resveratrol stimulated p53 accumulation and activity only weakly and with delayed kinetics and neither the increased levels nor the activity affected apoptosis detectably. The apoptosis agonist Bax was overproduced in response to resveratrol regardless of p53 status, yet the kinetics of Bax expression were influenced by p53. Remarkably, apoptosis was preceded by mitochondrial proliferation and signs of epithelial differentiation. Thus, resveratrol triggers a p53-independent apoptotic pathway in HCT 116 cells that may be linked to differentiation. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:615 / 622
页数:8
相关论文
共 37 条
[1]   DNA breakage by resveratrol and Cu(II): reaction mechanism and bacteriophage inactivation [J].
Ahmad, A ;
Asad, SF ;
Singh, S ;
Hadi, SM .
CANCER LETTERS, 2000, 154 (01) :29-37
[2]  
BEERE HM, 1993, ANTI-CANCER DRUG DES, V8, P299
[3]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[4]   Requirement for p53 and p21 to sustain G2 arrest after DNA damage [J].
Bunz, F ;
Dutriaux, A ;
Lengauer, C ;
Waldman, T ;
Zhou, S ;
Brown, JP ;
Sedivy, JM ;
Kinzler, KW ;
Vogelstein, B .
SCIENCE, 1998, 282 (5393) :1497-1501
[5]  
CHANTRET I, 1988, CANCER RES, V48, P1936
[6]  
Clément MV, 1998, BLOOD, V92, P996
[7]  
CUPLER EJ, 1995, ACTA NEUROPATHOL, V90, P1
[8]   Resveratrol arrests the cell division cycle at S/G2 phase transition [J].
Della Ragione, F ;
Cucciolla, V ;
Borriello, A ;
Della Pietra, V ;
Racioppi, L ;
Soldati, G ;
Manna, C ;
Galletti, P ;
Zappia, V .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (01) :53-58
[9]   Resveratrol, a remarkable inhibitor of ribonucleotide reductase [J].
Fontecave, M ;
Lepoivre, M ;
Elleingand, E ;
Gerez, C ;
Guittet, O .
FEBS LETTERS, 1998, 421 (03) :277-279
[10]   Resveratrol selectively inhibits leukemia cells:: a prospective agent for ex vivo bone marrow purging [J].
Gautam, SC ;
Xu, YX ;
Dumaguin, M ;
Janakiraman, N ;
Chapman, RA .
BONE MARROW TRANSPLANTATION, 2000, 25 (06) :639-645